Mengis Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$591K Buy
1,131
+620
+121% +$317K 0.09% 152
2026
Q2
$254K Buy
511
+11
+2% +$4.88K 0.04% 202
2026
Q1
$223K Hold
500
– – 0.04% 203
2025
Q4
$227K Buy
+500
New +$216K 0.04% 199
2025
Q3
– Sell
-500
Closed -$223K – 211
2025
Q2
$223K Buy
+500
New +$230K 0.05% 186

Other funds holding VRTX

Mengis Capital Management's VRTX Position: Q3 2026 in Review

Mengis Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 121% in Q3 2026, buying an estimated $317K and bringing the position to 1,131 shares worth $591K. The position accounts for 0.09% of the portfolio, ranked #152.

Mengis Capital Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,796 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Mengis Capital Management held 1,131 shares of Vertex Pharmaceuticals worth $591K as of Q3 2026.
  • Mengis Capital Management bought 620 Vertex Pharmaceuticals shares in Q3 2026, an estimated $317K.
  • Vertex Pharmaceuticals made up 0.09% of Mengis Capital Management's portfolio in Q3 2026, its #152 holding.
  • Mengis Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,796 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Mengis Capital Management's 13F filing for Q3 2026, filed 13 Oct 2026.